Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | SNCA | P37840 | 5/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CTRC | Q99895 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394695 | 1.00 | APP (1.00) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL644678 | 1.00 | APP (1.00) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL29363540 | 1.00 | APP (1.00) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL13343863 | 0.87 | MAPT (0.76) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL3569139 | 0.87 | MAPT (0.76) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL13343862 | 0.87 | MAPT (0.76) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL6001142 | 0.85 | PDGFRB (0.73) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL5481962 | 0.83 | PDGFRB (0.72) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL5481961 | 0.83 | PDGFRB (0.72) | APPMAPTSNCAPDGFRBMEN1 | |
| SCHEMBL1848787 | 0.83 | PDGFRB (0.70) | APPMAPTSNCAPDGFRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | Acclaim BioMed USA LLC (US) | 2019-10-22 | — | — | US | claimed |
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160201111-A1 | Method and Apparatus for Measuring Protein Post-Translational Modification | UNITED STATES GOVERNMENT | 2016-07-14 | — | — | US | claimed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | claimed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | claimed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | claimed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | claimed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | claimed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250215396-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12281329-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250043246-A1 | ENRICHMENT OF NKX6.1 AND C-PEPTIDE CO-EXPRESSING CELLS DERIVED IN VITRO FROM STEM CELLS | NOVO NORDISK AS (DK) | 2025-02-06 | — | — | US | disclosed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | SCHERING CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090087919-A1 | Method and Apparatus for Measuring Protein Post-Translational Modification | CALDERA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | MERCK & CO., INC. | 2007-05-24 | — | — | US | disclosed |
| US-20060241067-A1 | Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| WO-2004001384-A2 | METHODS FOR INHIBITING ANGIOGENESIS, CELL MIGRATION, CELL ADHESION, AND CELL SURVIVAL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | APP 4052/4885MAPT 2839/4885SNCA 4102/4885 |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | HDAC5, HDAC1, HDAC4 | APP 4785/4885MAPT 2630/4885SNCA 4608/4885 |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | MMP1, HES1, COLGALT1 | APP 1943/4885MAPT 4019/4885SNCA 4547/4885 |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | MMP1, HES1, COLGALT1 | APP 1943/4885MAPT 4019/4885SNCA 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.